JP2014502631A - 癌治療用医薬組成物 - Google Patents
癌治療用医薬組成物 Download PDFInfo
- Publication number
- JP2014502631A JP2014502631A JP2013548916A JP2013548916A JP2014502631A JP 2014502631 A JP2014502631 A JP 2014502631A JP 2013548916 A JP2013548916 A JP 2013548916A JP 2013548916 A JP2013548916 A JP 2013548916A JP 2014502631 A JP2014502631 A JP 2014502631A
- Authority
- JP
- Japan
- Prior art keywords
- mycobacterium
- cancer
- desmocollin
- patients
- survival
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 65
- 201000011510 cancer Diseases 0.000 title claims abstract description 34
- 238000011282 treatment Methods 0.000 title claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 title description 8
- 241001494992 Mycobacterium indicus pranii Species 0.000 claims abstract description 41
- 230000004083 survival effect Effects 0.000 claims abstract description 36
- 101710157874 Desmocollin-3 Proteins 0.000 claims abstract description 34
- 102100037709 Desmocollin-3 Human genes 0.000 claims abstract description 33
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 18
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 206010041823 squamous cell carcinoma Diseases 0.000 description 14
- 229930012538 Paclitaxel Natural products 0.000 description 12
- 229960001592 paclitaxel Drugs 0.000 description 12
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 12
- 238000002512 chemotherapy Methods 0.000 description 11
- 208000009956 adenocarcinoma Diseases 0.000 description 10
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 10
- 229960004316 cisplatin Drugs 0.000 description 10
- 238000003364 immunohistochemistry Methods 0.000 description 10
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 206010005003 Bladder cancer Diseases 0.000 description 5
- 206010062016 Immunosuppression Diseases 0.000 description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 238000011221 initial treatment Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 201000005112 urinary bladder cancer Diseases 0.000 description 5
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 3
- 229960005079 pemetrexed Drugs 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000006375 Desmocollins Human genes 0.000 description 2
- 108010019063 Desmocollins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 208000003849 large cell carcinoma Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000002658 Thyroid Nuclear Factor 1 Human genes 0.000 description 1
- 108010057966 Thyroid Nuclear Factor 1 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 208000037842 advanced-stage tumor Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
0.1 mlの各投与量は、以下を含有する:
マイコバクテリウムw(加熱死菌) 0.50 × 109
塩化ナトリウム、腹腔内 0.90% w/v
チオメロサール、腹腔内 0.01% w/v(保存料として)
注射用水、腹腔内 0.1 mlに定容
健常人に、ランダムにマイコバクテリウムw 0.1 mlおよびPBS(対照)を皮下投与した。7日後に採血し、PBMCを単離した。単離物から全RNAを抽出した。全RNAを用いて、世界的なヒトマイクロアレイに対する、マイクロアレイデータを作り出した。データを、対照に対する倍数変化として解釈した。データから、デスモコリン-3遺伝子が4倍に過剰発現することが示される。他のデスモコリンには影響しない。また、TTF-1遺伝子にも影響しない。
以下は、デスモコリン-3について評価した細胞系のリストである(表1)。
手術中に除去された腫瘍の切片を、デスモコリン-3の存在の有無について染色した。腫瘍の薄層パラフィン切片を、DSC 3に特異的な抗体を使用して、免疫組織化学の標準的なプロトコルで染色した。簡単な染色手法は、PBSによる洗浄を含む。その後、1:1000に希釈した一次抗体(抗DSC-3ヤギポリクローナル)で一晩染色し、二次抗体(ヤギ抗マウスIgG-FITC)で30分染色した。
非盲検の多中心性ランダム比較対象臨床試験において、進行性非小細胞肺癌患者の全生存の向上に対する効果について、マイコバクテリウムwをパクリタキセルおよびシスプラチンと組み合わせて評価した。
試験治療群に、21日のサイクルの1日目にパクリタキセル+シスプラチンを静注し、全部で4サイクル行った。加えて、化学療法の最初のサイクルの少なくとも1週間前、およびその後、化学療法の全てのサイクルの2週目と3週目に、マイコバクテリウムwを皮内投与した。
・組織学的または細胞学的に確認された、非小細胞肺癌のステージIIIBまたはIV。
・年齢:18歳以上
・ECOGステータスが0-1の範囲
・絶対好中球数 ≧ 1500/mm3、血小板数 ≧ 1,00,000/mm3
・ヘモグロビン ≧ 9.0g/dL
・ASTおよびALT 正常上限(ULN)の2.5倍以下(肝転移が存在する場合はULNの5倍)
・ビリルビン ULNの1.5倍を超えない(肝への侵襲がある場合はULNの3倍)
・クレアチニン ≦ 正常上限(ULN)以下
・試験の参加前に、妊娠の可能性がある女性については、妊娠検査が陰性
・文書によるインフォームド・コンセントの書面を理解する能力および書面にサインする意思
・試験の参加前に、細胞毒性を有する化学療法または放射線療法を受けていた患者
・系統的脳転移を有する患者
・パクリタキセル、シスプラチンまたはマイコバクテリウムwまたはそれらの成分のいずれかによるアレルギー反応の既往
・妊婦または授乳婦
・研究の必要条件のコンプライアンスを制限する可能性がある、コントロール不良の併発性疾患
・HIV陽性患者
・以前に脾臓摘出
報告された全ての分析はプロトコルの通りである。生存は、無作為化からあらゆる原因による死亡までの時間として規定し、無進行生存は、無作為化から文書化された疾患の進行または死亡までの時間として規定した。
全部で221名の患者が試験に参加し、そのうち109名を試験治療群に、112名を対照治療群に割り当てた。両群は全ての基本特性において同等であった(表4)。
BCG難治性膀胱癌患者11例において、TUR(経尿道的電気切除術)を実施した。0.1 mlのMwを皮内投与した後、2週間毎の投与を6回、4週間毎の投与を6回、8週間毎の投与を3回行った。15ヶ月を超える寛解を維持した患者は、デスモコリン-3陽性の腫瘍であった。3ヶ月未満で腫瘍が再発した他の患者は、デスモコリン-3陰性の腫瘍であった。
Claims (7)
- デスモコリン-3を発現する癌の治療における使用のための、マイコバクテリウムw。
- 請求項1に記載の使用のための、請求項1に係るマイコバクテリウムwであって、前記の癌が、非小細胞肺癌の扁平上皮型である、マイコバクテリウムw。
- 請求項1または2に記載の使用のための、請求項1または2に係るマイコバクテリウムwであって、前記の癌を罹患する患者の癌細胞が、デスモコリン-3を発現することを決定されている、マイコバクテリウムw。
- 請求項1〜3のいずれか一項に記載の使用のための、請求項1〜3のいずれか一項に係るマイコバクテリウムwであって、前記のマイコバクテリウムwが、デスモコリン-3を発現する癌を罹患する患者の生存を向上させる、マイコバクテリウムw。
- 請求項1〜4のいずれか一項に記載の使用のための、請求項1〜4のいずれか一項に係るマイコバクテリウムwであって、前記のマイコバクテリウムwが、投与量当り、細胞を106個より多い投与量で使用される、マイコバクテリウムw。
- 請求項1〜5のいずれか一項に記載の使用のための、請求項1〜5のいずれか一項に係るマイコバクテリウムwであって、前記のマイコバクテリウムwが、少なくとも1つの他の治療薬またはモダリティと組み合わせて使用される、マイコバクテリウムw。
- 請求項6に記載の使用のための、請求項6に係るマイコバクテリウムwであて、前記の他の治療薬またはモダリティが、化学療法剤である、マイコバクテリウムw。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN92/MUM/2011 | 2011-01-11 | ||
IN92MU2011 | 2011-01-11 | ||
PCT/IB2012/050120 WO2012095789A1 (en) | 2011-01-11 | 2012-01-10 | Pharmaceutical composition for treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014502631A true JP2014502631A (ja) | 2014-02-03 |
JP5889335B2 JP5889335B2 (ja) | 2016-03-22 |
Family
ID=54264167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013548916A Active JP5889335B2 (ja) | 2011-01-11 | 2012-01-10 | 癌治療用医薬組成物 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20130295648A1 (ja) |
EP (1) | EP2663318B1 (ja) |
JP (1) | JP5889335B2 (ja) |
CN (1) | CN103338779B (ja) |
AU (1) | AU2012206322B2 (ja) |
CA (1) | CA2824417C (ja) |
ES (1) | ES2536842T3 (ja) |
PL (1) | PL2663318T3 (ja) |
RU (1) | RU2580888C2 (ja) |
WO (1) | WO2012095789A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012206322B2 (en) * | 2011-01-11 | 2016-09-01 | Cadila Pharmaceuticals Limited | Pharmaceutical composition for treating cancer |
JP6421208B2 (ja) * | 2017-02-28 | 2018-11-07 | カディラ ファーマシューティカルズ リミテッド | がん抗原 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003049751A1 (en) * | 2001-12-10 | 2003-06-19 | Bakulesh Mafatlal Khamar | The process of manufacturing a pharmaceutical composition useful for management of cancer |
JP2005528332A (ja) * | 2001-12-10 | 2005-09-22 | カーマー,バクレシュ,マファトラル | 癌を治療する方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100572540C (zh) * | 2002-04-16 | 2009-12-23 | 成都永安制药有限公司 | 包括表达丙氨酸脱氢酶、丝氨酸脱水酶和/或谷氨酰胺合成酶的重组卡介苗菌株的结核病疫苗 |
US20100086911A1 (en) * | 2005-03-03 | 2010-04-08 | Ryosuke Katsuyama | Preventive/therapeutic agent for cancer |
EP2131858A4 (en) * | 2007-03-20 | 2011-11-23 | Cadila Pharmaceuticals Ltd | P38 INHIBITORS |
AU2012206322B2 (en) * | 2011-01-11 | 2016-09-01 | Cadila Pharmaceuticals Limited | Pharmaceutical composition for treating cancer |
WO2013005164A2 (en) * | 2011-07-05 | 2013-01-10 | Cadila Pharmaceuticals Limited | Cancer antigen |
-
2012
- 2012-01-10 AU AU2012206322A patent/AU2012206322B2/en active Active
- 2012-01-10 RU RU2013136780/15A patent/RU2580888C2/ru active
- 2012-01-10 CA CA2824417A patent/CA2824417C/en active Active
- 2012-01-10 CN CN201280007529.5A patent/CN103338779B/zh active Active
- 2012-01-10 US US13/978,923 patent/US20130295648A1/en not_active Abandoned
- 2012-01-10 JP JP2013548916A patent/JP5889335B2/ja active Active
- 2012-01-10 ES ES12702318.2T patent/ES2536842T3/es active Active
- 2012-01-10 PL PL12702318T patent/PL2663318T3/pl unknown
- 2012-01-10 EP EP12702318.2A patent/EP2663318B1/en active Active
- 2012-01-10 WO PCT/IB2012/050120 patent/WO2012095789A1/en active Application Filing
-
2015
- 2015-02-23 US US14/628,534 patent/US9415078B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003049751A1 (en) * | 2001-12-10 | 2003-06-19 | Bakulesh Mafatlal Khamar | The process of manufacturing a pharmaceutical composition useful for management of cancer |
JP2005528332A (ja) * | 2001-12-10 | 2005-09-22 | カーマー,バクレシュ,マファトラル | 癌を治療する方法 |
Non-Patent Citations (4)
Title |
---|
JPN6015038128; JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY Vol.22, 2008, p.1089-93 * |
JPN6015038129; JOURNAL OF THE INDIAN MEDICAL ASSOCIATION Vol.101, No.2, 2003, p.118, 120 * |
JPN6015038130; JOURNAL OF THE INDIAN MEDICAL ASSOCIATION Vol.101, No.9, 2003, p.559-60 * |
JPN6015038131; Wun-Jae Kim et al: 'Predictive value of progression-related gene classifier in primary non-muscle invasive bladder c' MOLECULAR CANCER Vol.9, 2010 * |
Also Published As
Publication number | Publication date |
---|---|
PL2663318T3 (pl) | 2015-08-31 |
US20150290255A1 (en) | 2015-10-15 |
ES2536842T3 (es) | 2015-05-29 |
US20130295648A1 (en) | 2013-11-07 |
AU2012206322B2 (en) | 2016-09-01 |
EP2663318B1 (en) | 2015-03-18 |
AU2012206322A1 (en) | 2013-08-29 |
EP2663318A1 (en) | 2013-11-20 |
CA2824417A1 (en) | 2012-07-19 |
WO2012095789A1 (en) | 2012-07-19 |
RU2013136780A (ru) | 2015-02-20 |
RU2580888C2 (ru) | 2016-04-10 |
CA2824417C (en) | 2019-02-26 |
CN103338779B (zh) | 2015-12-23 |
CN103338779A (zh) | 2013-10-02 |
US9415078B2 (en) | 2016-08-16 |
JP5889335B2 (ja) | 2016-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hirai et al. | A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L | |
Grisham et al. | Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer | |
KR102502545B1 (ko) | Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품 | |
AU2018287519B2 (en) | IL-1beta binding antibodies for use in treating cancer | |
Wick et al. | Current status and future directions of anti-angiogenic therapy for gliomas | |
JP2020172487A (ja) | トラスツズマブ−mcc−dm1及びペルツズマブにより早期の乳癌を処置する方法 | |
US20230093147A1 (en) | Methods and compositions relating to improved combination therapies | |
JP6914336B2 (ja) | 進行したher2発現がんの治療 | |
JP2024009886A (ja) | 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 | |
AU2017355432A1 (en) | Treatment of HER2-positive breast cancer | |
JP2020514281A5 (ja) | ||
Gollins | Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer | |
JP5889335B2 (ja) | 癌治療用医薬組成物 | |
US20230130698A1 (en) | Enhanced efficacy of combination of gemcitabine and phosphatidylserine-targeted nanovesicles against pancreatic cancer | |
US20240156908A1 (en) | USE OF sEphB4-HSA FUSION PROTEIN AS A FIRST-LINE THERAPY IN CANCER TREATMENT | |
JP4621923B2 (ja) | 膵癌用抗癌剤の耐性検査マーカー、膵癌用抗癌剤の補助治療薬 | |
Chen et al. | RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China | |
CA3173797A1 (en) | Method for allowing immune cells infiltration in tumors | |
CN116348141A (zh) | 辅助性德瓦鲁单抗与化疗组合用于治疗癌症 | |
Ohnuma et al. | A multidisciplinary treatment approach using docetaxel, nedaplatin, and 5-FU for advanced esophageal cancer | |
KR20240060625A (ko) | 암 치료를 위한 삼중제 요법 | |
REARRANGEMENT | non-small cell lung cancer, locally advanced |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160202 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5889335 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |